Donahue, R. N., Schlom, J., Toney, N. J., Isaacs, C., Lynce, F., Mainor, C., & Lynch, M. T. Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy. BMJ Publishing Group.
Chicago Style (17th ed.) CitationDonahue, Renee N., Jeffrey Schlom, Nicole J. Toney, Claudine Isaacs, Filipa Lynce, Candace Mainor, and Megan T. Lynch. Serum Analytes as Predictors of Disease Recurrence and the Duration of Invasive Disease-free Survival in Patients with Triple Negative Breast Cancer Enrolled in the OXEL Trial Treated with Immunotherapy, Chemotherapy, or Chemoimmunotherapy. BMJ Publishing Group.
MLA (9th ed.) CitationDonahue, Renee N., et al. Serum Analytes as Predictors of Disease Recurrence and the Duration of Invasive Disease-free Survival in Patients with Triple Negative Breast Cancer Enrolled in the OXEL Trial Treated with Immunotherapy, Chemotherapy, or Chemoimmunotherapy. BMJ Publishing Group.